Why JBIO Stock slipped -1.26% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, JBIO carries an RQD Score of 31 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars score as follows: Fundamental Cash Engine 8/20 (ROIC -35%; FCF yield -10.48%), Whale 13F Flow 4/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 6/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are Insider Conviction and Whale 13F Flow, which together indicate limited evidence of informed-capital support in the source data. The Cash Engine pillar reflects negative return on invested capital and negative free-cash-flow yield, meaning the business is currently consuming rather than generating cash on a per-dollar-invested basis. The Forensic Balance Sheet pillar is the relative bright spot, with an Altman Z of 2.5 and a Debt/Equity of 0.5, though a Piotroski F of 2/9 signals weak financial-quality signals. Upside drivers in the source data are limited to the news flow described below; valuation cannot be assessed from the available P/E or EV/EBITDA figures, which are not available in source data. The rating is a quantitative screen and does not constitute a recommendation.

Per the SEC financials, reported revenue is $0.0M in each period, with operating losses and net losses in all three years, and the FY 2025 net loss of $-127.4M is the largest of the periods shown. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. The Piotroski F-Score is 2/9 and the Altman Z-Score is 2.5, both per the Roarable RQD rating. The balance sheet shows cash of $88.4M at FY 2025 and a Debt/Equity ratio of 0.5, while period-level debt is not available in source data.

The news wire contains six items, all tagged YELLOW with the MARKET WIRE impact label. The sources report that Jade Biosciences plans to highlight advancement of its JADE101 development program at the American Society of Nephrology Kidney Week 2026. A Stock Titan item states that about 169,000 Americans have IgA kidney disease and that Jade expects its trial to start this quarter. BTIG is reported to maintain a Buy rating with a $77 target price, reiterated in a separate item. A TradingView item and an Investing.com Canada item reference fair-value and decline analysis, including a 48% decline. Risk watch items include the negative operating and free-cash-flow trend, the absence of revenue, and the 52-week range of $8.36 to $28 against the current price of 14.24. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Per the analyst data section, no analyst data is available. The BTIG Buy rating and $77 target appear only in the news wire headlines and are not corroborated by a structured analyst dataset. Per the holders section, no 13F, Form 4, or Congressional trade data is available in the holders section. The Whale 13F Flow and Insider Conviction pillars in the RQD rating score 4/20 and 3/20 respectively, per the Roarable RQD rating.

• What are JADE101's clinical stage, trial design, and timeline, given the news wire reference to a trial start this quarter?
• What is the company's cash runway relative to the FY 2025 operating loss of $-113.5M and cash balance of $88.4M?
• Why are period-level debt and EPS values not available in source data, and what is the total debt obligation?
• What is the basis for the BTIG $77 price target relative to the current price of 14.24?
• What are the company's products, partnerships, or licensing arrangements, which are not described in source data?